scholarly journals Sodium-Glucose Cotransporter-2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis After Orthotopic Heart Transplant in a Prediabetic Patient: A Case Report

2021 ◽  
Author(s):  
Beda M. Cha ◽  
Roland Davoudi ◽  
Michael C. DiVita ◽  
Ashley M. Fan ◽  
Megan Y. Kamath
Keyword(s):  
Case Report ◽  
Diabetic Ketoacidosis ◽  
Heart Transplant ◽  
Orthotopic Heart Transplant ◽  
Sodium Glucose Cotransporter ◽  
Euglycemic Diabetic Ketoacidosis

scholarly journals Euglycemic Diabetic Ketoacidosis Precipitated by SGLT-2 Inhibitor Use, Pericarditis, and Fasting: A Case Report

2020 ◽  
Vol 4 (3) ◽  
pp. 389-392
Author(s):  
Rebecca Mendelsohn ◽  
Anabelle Taveras ◽  
Benjamin Mazer ◽  
Lisa Clayton
Keyword(s):  
Case Report ◽  
Diabetic Ketoacidosis ◽  
Oral Intake ◽  
Serum Glucose ◽  
Acute Pericarditis ◽  
Sodium Glucose Cotransporter ◽  
Life Threatening ◽  
Underlying Causes ◽  
Euglycemic Diabetic Ketoacidosis

Introduction: Diabetic ketoacidosis (DKA) is a potentially life-threatening complication of diabetes mellitus. Less prevalent is euglycemic DKA (eDKA)—DKA with serum glucose less than 200 mg/dL; however, it is increasing in frequency with the introduction of sodium glucose cotransporter 2 (SGLT-2) inhibitors for treatment of type 2 diabetes. Case Report: We report a case of SGLT-2 inhibitor-associated eDKA presenting with concurrent acute pericarditis. Discussion: Our case suggests that the cause of eDKA can be multifactorial when decreased oral intake occurs in the setting of an acute cause of physiologic stress. Conclusion: Prompt recognition of eDKA in the emergency department may allow earlier diagnosis and treatment directed at one or more of its underlying causes.

scholarly journals Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis

2021 ◽  
Vol 11 (2) ◽  
pp. 216-218
Author(s):  
Marta Brandão Calçada ◽  
Luís Fernandes ◽  
Rita Soares Costa ◽  
Sara Montezinho ◽  
Filipa Martins Duarte ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Ketoacidosis ◽  
Drug Class ◽  
Clinical Suspicion ◽  
Laboratory Findings ◽  
Sodium Glucose Cotransporter ◽  
History Of ◽  
High Degree ◽  
Euglycemic Diabetic Ketoacidosis

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the most recently approved drug class for the treatment of type 2 diabetes mellitus (T2D). Although they are largely well-tolerated, their intake has been associated with euglycemic diabetic ketoacidosis (DKA) in some rare cases. We report the case of a 70-year-old male with type 2 diabetes and no history of DKA, who started therapy with empagliflozin one day before presenting with acute pancreatitis and laboratory findings consistent with euglycemic DKA. SGLT2i can induce euglycemic DKA from the first dose. Given the atypical presentation, a high degree of clinical suspicion is required to recognize this complication.

scholarly journals Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin

2017 ◽  
Vol 5 (2) ◽  
pp. 232470961771273 ◽  
Author(s):  
Daniel A. Kelmenson ◽  
Kelsey Burr ◽  
Yusra Azhar ◽  
Paul Reynolds ◽  
Chelsea A. Baker ◽  
...  
Keyword(s):  
Diabetic Ketoacidosis ◽  
Sodium Glucose Cotransporter ◽  
Euglycemic Diabetic Ketoacidosis

scholarly journals Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Erasmia Sampani ◽  
Pantelis Sarafidis ◽  
Chrysostomos Dimitriadis ◽  
Efstratios Kasimatis ◽  
Dimitra Daikidou ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Diabetic Patient ◽  
Diabetic Ketoacidosis ◽  
Euglycemic Diabetic Ketoacidosis ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document